NCT03459729View on ClinicalTrials.gov

Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

February 16, 2022

Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
DRUG

Antitumor B

Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).

Trial Locations (1)

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Medical College of Wisconsin

OTHER

NCT03459729 - Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | Biotech Hunter | Biotech Hunter